What is Inception Sciences?
Inception Sciences operates as a sophisticated biotechnology incubator and drug discovery engine. By integrating multi-disciplinary wetlab capabilities with a team of seasoned drug hunters, the firm identifies and nurtures high-potential scientific breakthroughs. Their business model is centered on the creation of transformational biotech entities, effectively bridging the gap between early-stage academic research and commercial-grade clinical development. This strategic positioning allows Inception Sciences to maintain a robust pipeline of therapeutic candidates across diverse medical domains, ensuring that innovation is not merely theoretical but actionable within the pharmaceutical market.
How much funding has Inception Sciences raised?
Inception Sciences has raised a total of $4.1M across 1 funding round:
Series A
$4.1M
Series A (2015): $4.1M with participation from Inserm Transfert Initiative, Fonds de solidarit_, and Versant Ventures
Key Investors in Inception Sciences
Inserm Transfert Initiative
Inserm Transfert Initiative is a specialized entity focused on the commercialization of medical research, bridging the gap between laboratory discoveries and practical healthcare applications.
Fonds de solidarité FTQ
A prominent Canadian private equity and venture capital firm that provides strategic financing to support business growth, acquisitions, and early-stage ventures.
Versant Ventures
A global venture capital firm with extensive experience in building biotechnology companies, managing significant assets, and facilitating successful IPOs and M&A transactions.
What's next for Inception Sciences?
With the recent capital injection, Inception Sciences is well-positioned to accelerate its internal R&D initiatives and expand its portfolio of therapeutic ventures. The firm is expected to prioritize the advancement of its lead candidates through preclinical milestones, while simultaneously exploring new collaborative partnerships to enhance its drug discovery platform. As the company scales, the focus will likely shift toward optimizing its operational efficiency and strengthening its intellectual property portfolio, thereby increasing the valuation of its subsidiary ventures. This strategic expansion is critical for maintaining a competitive edge in the rapidly evolving life sciences sector, where the demand for novel, high-impact medical solutions remains at an all-time high.
See full Inception Sciences company page
